Approximately 10% of patients with metastatic castration-resistant prostate cancer have alterations in the BRCA1 or BRCA2 genes which are associated…
NOTICIAS
Laboratory tests with mice reveal ‘exciting’ new strategy that could transform triple-negative breast cancer into a manageable disease Researchers at…
The biotech company Peptomyc SL announced today that it has been awarded €5 million blended financing from the Horizon Europe,…
The kick-off meeting of PragmaTIL, a project that will finance a pioneering academic clinical trial in advanced therapies, coordinated by…
The Breast Cancer Research Foundation (BCRF) will commit $60.2 million to breast cancer research in 2023-2024, supporting more than 250…
A new joint effort by the Hospital del Mar Research Institute, the Vall d’Hebron Institut d’Oncologia (VHIO), IDIBELL, and the…
Inaugurated by Andrés Cervantes (Valencia, Spain), President of the European Society for Medical Oncology (ESMO) and ESMO Congress 2023, this…
Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…
Presented during Presidential session I (1) at the 2023 Congress of the European Society for Medical Oncology (ESMO), 20-24 October…
Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…
